Sethuraman Natarajan
President, Research & Develop.
Sethuraman Natarajan has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Sep 3, 2026.
On the most recent filing, Sethuraman Natarajan is listed as President, Research & Develop. at Entrada Therapeutics, Inc. Inside the rolling window, Sethuraman Natarajan reported no open-market purchases and 1 open-market sale totaling $399K in TRDA.
Companies traded
Other insiders at TRDA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$399K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Sethuraman Natarajan made?
Sethuraman Natarajan has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does Sethuraman Natarajan trade?
Sethuraman Natarajan has filed SEC Form 4 disclosures for 1 company, including TRDA.
When was Sethuraman Natarajan's most recent SEC Form 4 filing?
Sethuraman Natarajan's most recent SEC Form 4 filing on Tracefour is dated Sep 3, 2026.
What is Sethuraman Natarajan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sethuraman Natarajan is listed as President, Research & Develop..
What is Sethuraman Natarajan's total buy and sell value in the current window?
Inside the rolling retention window, Sethuraman Natarajan bought $0 and sold $399K based on SEC Form 4 filings.
What was Sethuraman Natarajan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 25,907 TRDA shares on 2026-05-04, worth $399K, per SEC Form 4 filings.